Shots:

• The NMPA has cleared an IND application for a P-III study to evaluate the efficacy and safety of KX-826 in patients with male AGA across 20+ sites in China. The first patient is expected to enroll in early Jan 2022
• The 1EPs of the trial is the change from baseline in non-vellus TAHC at the end of 24wks.
• On  Sept 08, 2021, the P-II trial meet its 1EPs & demonstrated a good efficacy and safety profile of KX-826. On Jul 11, 2021, the therapy has received the US FDA’s approval for AGA

Ref: Kintor Pharma | Image: Kintor Pharma